Shares of Antares Pharma Inc (NASDAQ:ATRS) have earned a consensus rating of “Buy” from the six analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $5.04.
Separately, BidaskClub lowered Antares Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, August 20th.
A number of large investors have recently added to or reduced their stakes in the stock. River & Mercantile Asset Management LLP acquired a new position in Antares Pharma during the 2nd quarter valued at approximately $2,603,000. Nuveen Asset Management LLC acquired a new position in Antares Pharma during the 2nd quarter valued at approximately $2,252,000. Jane Street Group LLC acquired a new position in Antares Pharma during the 2nd quarter valued at approximately $362,000. Vanguard Group Inc. boosted its position in Antares Pharma by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 7,419,037 shares of the specialty pharmaceutical company’s stock valued at $24,409,000 after purchasing an additional 110,433 shares during the period. Finally, Private Advisor Group LLC boosted its position in Antares Pharma by 21.2% during the 2nd quarter. Private Advisor Group LLC now owns 125,251 shares of the specialty pharmaceutical company’s stock valued at $412,000 after purchasing an additional 21,871 shares during the period. Institutional investors and hedge funds own 38.73% of the company’s stock.
Antares Pharma (NASDAQ:ATRS) last issued its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.03. The company had revenue of $28.43 million during the quarter, compared to analyst estimates of $21.66 million. Antares Pharma had a negative return on equity of 9.67% and a negative net margin of 4.03%. Equities analysts expect that Antares Pharma will post -0.08 earnings per share for the current year.
Antares Pharma Company Profile
Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
Read More: Most Active Stocks
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.